Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PM21 particles
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- Cell Therapies, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
PM21 particles are nano-scale plasma membrane vesicles derived from a modified K562 cell line (K562-mb21-41BBL) engineered to express 4-1BB ligand (4-1BBL) and membrane-bound interleukin-21 (mbIL-21). These particles serve as a feeder cell-free platform for the robust ex vivo and in vivo expansion and activation of natural killer (NK) cells for cancer immunotherapy. By providing localized co-stimulatory signals, PM21 particles induce high levels of NK cell proliferation and enhance their cytotoxic activity against various malignancies, including acute myeloid leukemia (AML) and solid tumors like ovarian cancer. The technology was developed by researchers at the University of Central Florida and Nationwide Children's Hospital, utilizing cell lines provided by Kiadis Pharma (a Sanofi company).
- Other names
- plasma membrane particlesPM21-particlePM-21-particlePM 21-particle
02
Targets
IL21R (Interleukin-21 receptor)TNFRSF9 (CD137 extracellular domain)
Beyond the preview
Go deeper on PM21 particles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PM21 particles.